Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

NCT02349386 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped Inability to recruit patients

Conditions

Cancer of the Prostate

Interventions

DRUG: BHR-200 (0.36% transdermal 17β-estradiol gel)
DRUG: Placebo

Sponsor

BHR Pharma, LLC

Collaborators

[object Object]
[object Object]